Abstract

Chronic rhinosinusitis (CRS) is inflammation of the nose and the paranasal sinuses, with symptoms lasting over 12 weeks. It has a
significant burden on the healthcare system. The usual treatment regimen today consists of local and/or systemic corticosteroids. However, local steroids might not yield a desired treatment effect in all patients while systemic steroids have a broad range of severe side effects. The likely future direction for some CRS patients is the use of biologic treatment. Various clinical studies have been launched in recent years with preliminary results showing great promise.